The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Belyashova A.S.

Burdenko Neurosurgical Center

Galkin M.V.

Burdenko National Medical Research Center for Neurosurgery

Antipina N.A.

Burdenko Neurosurgical Center

Pavlova G.V.

Burdenko National Medical Research Center of Neurosurgery

Golanov A.V.

Burdenko Neurosurgical Center

Cell cultures in assessing radioresistance of glioblastomas

Authors:

Belyashova A.S., Galkin M.V., Antipina N.A., Pavlova G.V., Golanov A.V.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2022;86(5): 126‑132

DOI: 10.17116/neiro202286051126

Views: 3613

Downloaded: 95

Download PDF (RU)
Download PDF
Contact the author
Table of contents

To cite this article:

Belyashova AS, Galkin MV, Antipina NA, Pavlova GV, Golanov AV. Cell cultures in assessing radioresistance of glioblastomas. Burdenko's Journal of Neurosurgery. 2022;86(5):126‑132. (In Russ., In Engl.)
https://doi.org/10.17116/neiro202286051126

 
МСФ на ЯМ
Close metadata

To date, no modern methods of treatment allow overcoming malignant potential of glial neoplasms and significant increase of survival. Analysis of glioblastoma radioresistance using cancer cell cultures is one of the perspective directions, as radiotherapy is standard and available treatment method for these neoplasms. This review summarizes current studies identifying many factors of radioresistance of glial tumors, such as hypoxia, microenvironment and metabolic features of tumor, stem cells, internal heterogeneity of tumor, microRNA, features of cell cycle, DNA damage and reparation. We obtained data on involvement of various molecular pathways in development of radioresistance such as MEK/ERK, c-MYC, PI3K/Akt, PTEN, Wnt, JAK/STAT, Notch, etc. Changes in activity of RAD51 APC, FZD1, LEF1, TCF4, WISP1, p53 and many others are determined in radioresistant cells. Further study of radioresistance pathways will allow development of specific target aptamers and inhibitors.

Keywords:

cancer cell culture
glioblastoma
radioresistance

Authors:

Belyashova A.S.

Burdenko Neurosurgical Center

Galkin M.V.

Burdenko National Medical Research Center for Neurosurgery

Antipina N.A.

Burdenko Neurosurgical Center

Pavlova G.V.

Burdenko National Medical Research Center of Neurosurgery

Golanov A.V.

Burdenko Neurosurgical Center

Received:

08.08.2022

Accepted:

19.08.2022

List of references:

  1. Stupp R, Mason WP, van den Bent, Martin J, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 2005;352(10):987-996.  https://doi.org/10.1056/nejmoa043330
  2. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine. 2014;370(8):709-722.  https://doi.org/10.1056/NEJMoa1308345
  3. Rapp M, Baernreuther J, Turowski B, Steiger H-J, Sabel M, Kamp MA. Recurrence Pattern Analysis of Primary Glioblastoma. World Neurosurgery. 2017;103:733-740.  https://doi.org/10.1016/j.wneu.2017.04.053
  4. McDonald MW, Shu H-KG, Curran WJ, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. International Journal of Radiation Oncology. Biology. Physics. 2011;79(1):130-136.  https://doi.org/10.1016/j.ijrobp.2009.10.048
  5. Graf R, Hildebrandt B, Tilly W, Sreenivasa G, Ullrich R, Maier-Hauff K, Felix R, Wust P. Dose-Escalated Conformal Radiotherapy of Glioblastomas — Results of a Retrospective Comparison Applying Radiation Doses of 60 and 70 Gy. Oncology Research and Treatment. 2005;28(6-7):325-330.  https://doi.org/10.1159/000085574
  6. Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or ≤ 20 cm2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. International Journal of Radiation Oncology, Biology, Physics. 2000;48(5):1351-1358. https://doi.org/10.1016/s0360-3016(00)01412-7
  7. Zhang Y, Dube C, Gibert M, Cruickshanks N, Wang B, Coughlan M, Yang Y, Setiady I, Deveau C, Saoud K, Grello C, Oxford M, Yuan F, Abounader R. The p53 Pathway in Glioblastoma. Cancers. 2018;10(9):297.  https://doi.org/10.3390/cancers10090297
  8. Pesenti C, Navone SE, Guarnaccia L, Terrasi A, Costanza J, Silipigni R, Guarneri S, Fusco N, Fontana L, Locatelli M, Rampini P, Campanella R, Tabano S, Miozzo M, Marfia G. The Genetic Landscape of Human Glioblastoma and Matched Primary Cancer Stem Cells Reveals Intratumour Similarity and Intertumour Heterogeneity. Stem Cells International. 2019;20192617030. https://doi.org/10.1155/2019/2617030
  9. LeBlanc VG, Trinh DL, Aslanpour S, Hughes M, Livingstone D, Jin D, Ahn BY, Blough MD, Cairncross JG, Chan JA, Kelly JJP, Marra MA. Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. Cancer Cell. 2022;40(4):379-392.e9.  https://doi.org/10.1016/j.ccell.2022.02.016
  10. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391-403.  https://doi.org/10.1016/j.ccr.2006.03.030
  11. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. British Journal of Radiology. 1953;26(312):638-648.  https://doi.org/10.1259/0007-1285-26-312-638
  12. Marampon F, Gravina GL, Zani BM, Popov VM, Fratticci A, Cerasani M, Di Genova D, Mancini M, Ciccarelli C, Ficorella C, Di Cesare E, Festuccia C. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay. International Journal of Oncology. 2014;44(6):2121-2131. https://doi.org/10.3892/ijo.2014.2358
  13. Li P, Zhou C, Xu L, Xiao H. Hypoxia enhances stemness of cancer stem cells in glioblastoma: An in vitro study. International Journal of Medical Sciences. 2013;10(4):399-407.  https://doi.org/10.7150/ijms.5407
  14. Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A, Tolliday N, Lamb J, Pantopoulos K, Golub T, Iliopoulos O. Small molecule inhibitors of HIF-2a translation link its 5’-UTR Iron-Responsive Element (IRE) to oxygen sensing. Molecular Cell. 2008;32(6):838-848.  https://doi.org/10.1016/j.molcel.2008.12.004
  15. Schiffer D, Annovazzi L, Casalone C, Corona C, Mellai M. Glioblastoma: Microenvironment and Niche Concept. Cancers. 2018;11(1):5.  https://doi.org/10.3390/cancers11010005
  16. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: Intrinsic characteristic or property of the ‘microenvironment‐stem cell unit’? Molecular Oncology. 2011;5(4):374-386.  https://doi.org/10.1016/j.molonc.2011.05.001
  17. Fidoamore A, Cristiano L, Antonosante A, d’Angelo M, Di Giacomo E, Astarita C, Giordano A, Ippoliti R, Benedetti E, Cimini A. Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. Stem Cells International. 2016;2016(18):1-17.  https://doi.org/10.1155/2016/6809105
  18. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, Kerbel RS. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Research. 2009;69(18):7243-7251. https://doi.org/10.1158/0008-5472.CAN-09-0167
  19. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, van der Heijden M, Moayedpardazi H, Correia AS, Soulet D, Major T, Menon J, Tabar V. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells. 2010;28(6):1019-1029. https://doi.org/10.1002/stem.429
  20. Farace C, Oliver JA, Melguizo C, Alvarez P, Bandiera P, Rama AR, Malaguarnera G, Ortiz R, Madeddu R, Prados J. Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells. PLoS One. 2015;10(7):e0134111. https://doi.org/10.1371/journal.pone.0134111
  21. Stanzani E, Martínez-Soler F, Mateos TM, Vidal N, Villanueva A, Pujana MA, Serra-Musach J, La Iglesia N de, Giménez-Bonafé P, Tortosa A. Radioresistance of mesenchymal glioblastoma initiating cells correlates with patient outcome and is associated with activation of inflammatory program. Oncotarget. 2017;8(43):73640-73653. https://doi.org/10.18632/oncotarget.18363
  22. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clinical Cancer Research. 2008;14(1):123-129.  https://doi.org/10.1158/1078-0432.CCR-07-0932
  23. Lopez-Bertoni H, Lal B, Li A, Caplan M, Guerrero-Cázares H, Eberhart CG, Quiñones-Hinojosa A, Glas M, Scheffler B, Laterra J, Li Y. DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2. Oncogene. 2015;34(30):3994-4004. https://doi.org/10.1038/onc.2014.334
  24. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, DePinho RA, Anderson DJ, Stiles CD, Rowitch DH. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007;53(4):503-517.  https://doi.org/10.1016/j.neuron.2007.01.009
  25. Veselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T, Relichova J. Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer. 2006;6:32.  https://doi.org/10.1186/1471-2407-6-32
  26. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular Cancer. 2006;5:67.  https://doi.org/10.1186/1476-4598-5-67
  27. Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Research. 2010;70(6):2455-2464. https://doi.org/10.1158/0008-5472.CAN-09-2505
  28. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Research. 2003;63(18):5821-5828.
  29. Chang C-J, Hsu C-C, Yung M-C, Chen K-Y, Tzao C, Wu W-F, Chou H-Y, Lee Y-Y, Lu K-H, Chiou S-H, Ma H-I. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochemical and Biophysical Research Communications. 2009;380(2):236-242.  https://doi.org/10.1016/j.bbrc.2009.01.040
  30. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120): 756-760.  https://doi.org/10.1038/nature05236
  31. Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. The Journal of Biological Chemistry. 2007;282(29):21206-21212. https://doi.org/10.1074/jbc.M703042200
  32. Li H-F, Kim J-S, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiation Oncology. 2009;4:43.  https://doi.org/10.1186/1748-717X-4-43
  33. Yaes RJ. Tumor heterogeneity, tumor size, and radioresistance. International Journal of Radiation Oncology - Biology - Physics. 1989;17(5):993-1005. https://doi.org/10.1016/0360-3016(89)90147-8
  34. Yin N, Xie T, Zhang H, Chen J, Yu J, Liu F. IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR. Oncology Letters. 2020;19(2):1322-1330. https://doi.org/10.3892/ol.2019.11148
  35. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. Journal of Experimental Medicine. 2011;208(2):313-326.  https://doi.org/10.1084/jem.20101470
  36. Vartanian A, Agnihotri S, Wilson MR, Burrell KE, Tonge PD, Alamsahebpour A, Jalali S, Taccone MS, Mansouri S, Golbourn B, Aldape KD, Zadeh G. Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. Oncotarget. 2016;7(43):69518-69535. https://doi.org/10.18632/oncotarget.11680
  37. Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP, Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski C, Stegh AH. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Reports. 2017;19(9):1858-1873. https://doi.org/10.1016/j.celrep.2017.05.014
  38. You W-C, Chiou S-H, Huang C-Y, Chiang S-F, Yang C-L, Sudhakar JN, Lin T-Y, Chiang I-P, Shen C-C, Cheng W-Y, Lin J-C, Shieh S-H, Chow K-C. Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma. Neuro-Oncology. 2013;15(10):1342-1352. https://doi.org/10.1093/neuonc/not077
  39. Sana J, Busek P, Fadrus P, Besse A, Radova L, Vecera M, Reguli S, Stollinova Sromova L, Hilser M, Lipina R, Lakomy R, Kren L, Smrcka M, Sedo A, Slaby O. Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival. Scientific Reports. 2018;8(1):2836. https://doi.org/10.1038/s41598-018-20929-6
  40. Møller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M. A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Molecular Neurobiology. 2013;47(1):131-144.  https://doi.org/10.1007/s12035-012-8349-7
  41. Deng X, Ma L, Wu M, Zhang G, Jin C, Guo Y, Liu R. miR-124 radiosensitizes human glioma cells by targeting CDK4. Journal of Neuro-Oncology. 2013;114(3):263-274.  https://doi.org/10.1007/s11060-013-1179-2
  42. Toraih EA, El-Wazir A, Abdallah HY, Tantawy MA, Fawzy MS. Deregulated MicroRNA Signature Following Glioblastoma Irradiation. Cancer Control. 2019;26(1):1073274819847226. https://doi.org/10.1177/1073274819847226
  43. Li W, Guo F, Wang P, Hong S, Zhang C. miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Current Molecular Medicine. 2014;14(1):185-195.  https://doi.org/10.2174/1566524013666131203103147
  44. Moskwa P, Zinn PO, Choi YE, Shukla SA, Fendler W, Chen CC, Lu J, Golub TR, Hjelmeland A, Chowdhury D. A functional screen identifies miRs that induce radioresistance in glioblastomas. Molecular Cancer Research. 2014;12(12):1767-1778. https://doi.org/10.1158/1541-7786.MCR-14-0268
  45. Marampon F, Megiorni F, Camero S, Crescioli C, McDowell HP, Sferra R, Vetuschi A, Pompili S, Ventura L, Felice F de, Tombolini V, Dominici C, Maggio R, Festuccia C, Gravina GL. HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells. Cancer Letters. 2017;3971-3911. https://doi.org/10.1016/j.canlet.2017.03.028
  46. Kowalski-Chauvel A, Modesto A, Gouaze-Andersson V, Baricault L, Gilhodes J, Delmas C, Lemarie A, Toulas C, Cohen-Jonathan-Moyal E, Seva C. Alpha-6 integrin promotes radioresistance of glioblastoma by modulating DNA damage response and the transcription factor Zeb1. Cell Death and Disease. 2018;9(9):872.  https://doi.org/10.1038/s41419-018-0853-x
  47. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, Valerie K. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biology and Therapy. 2009;8(8):730-738.  https://doi.org/10.4161/cbt.8.8.7927
  48. Hitoshi S, Alexson T, Tropepe V, Donoviel D, Elia AJ, Nye JS, Conlon RA, Mak TW, Bernstein A, van der Kooy D. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Development. 2002;16(7):846-858.  https://doi.org/10.1101/gad.975202
  49. Hitoshi S, Seaberg RM, Koscik C, Alexson T, Kusunoki S, Kanazawa I, Tsuji S, van der Kooy D. Primitive neural stem cells from the mammalian epiblast differentiate to definitive neural stem cells under the control of Notch signaling. Genes Development. 2004;18(15):1806-1811. https://doi.org/10.1101/gad.1208404
  50. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068. https://doi.org/10.1038/nature07385
  51. Wu JK, Ye Z, Darras BT. Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurgery. 1993;33(5):824-830.  https://doi.org/10.1227/00006123-199311000-00006
  52. Shu H-KG, Kim MM, Chen P, Furman F, Julin CM, Israel MA. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21BAX expression. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(24):14453-14458.
  53. Tompa M, Kalovits F, Nagy A, Kalman B. Contribution of the Wnt Pathway to Defining Biology of Glioblastoma. Neuromolecular Medicine. 2018;20(4): 437-451.  https://doi.org/10.1007/s12017-018-8514-x
  54. Lee Y, Lee J-K, Ahn SH, Lee J, Nam D-H. WNT signaling in glioblastoma and therapeutic opportunities. Laboratory Investigation. 2016;96(2):137-150.  https://doi.org/10.1038/labinvest.2015.140
  55. McCord M, Mukouyama Y-s, Gilbert MR, Jackson S. Targeting WNT Signaling for Multifaceted Glioblastoma Therapy. Frontiers in Cellular Neuroscience. 2017;11:318.  https://doi.org/10.3389/fncel.2017.00318
  56. Kim N, Kim SH, Kang S-G, Moon JH, Cho J, Suh C-O, Yoon H in, Chang JH. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data. Radiation Oncology. 2020;15(1):184.  https://doi.org/10.1186/s13014-020-01619-y
  57. Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, Chomel J-C, Karayan-Tapon L. A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells. BMC Cancer. 2016;16:604.  https://doi.org/10.1186/s12885-016-2647-9
  58. Ventero MP, Fuentes-Baile M, Quereda C, Perez-Valeciano E, Alenda C, Garcia-Morales P, Esposito D, Dorado P, Manuel Barbera V, Saceda M. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3. PLoS One. 2019;14(2)e0212581. https://doi.org/10.1371/journal.pone.0212581
  59. Tang Z, Dokic I, Knoll M, Ciamarone F, Schwager C, Klein C, Cebulla G, Hoffmann DC, Schlegel J, Seidel P, Rutenberg C, Brons S, Herold-Mende C, Wick W, Debus J, Lemke D, Abdollahi A. Radioresistance and Transcriptional Reprograming of Invasive Glioblastoma Cells. International Journal of Radiation Oncology, Biology, Physics. 2022;112(2):499-513.  https://doi.org/10.1016/j.ijrobp.2021.09.017
  60. Antipina NA, Smirnov GYu, Nikolaeva AA, Belyashova AS, Pavlova GV, Golanov AV. Physico-technical aspects of the experimental study of the effect of high radiation doses on human glioblastoma cell culture. Meditsinskaya fizika. 2019;(2):51-57. (In Russ).

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.